[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"generalized-lipodystrophy-gld\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:generalized-lipodystrophy-gld":20},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":16,"phases":4,"briefSummary":17,"conditions":18,"keywords":22,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":31,"locationsCount":4},"100417005","expanded-access-to-regn4461-for-patients-with-diseases-associated-with-deficient-leptin-signaling-100417005",false,"NCT04710056","Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling","Key Inclusion: N\u002FA\n\nKey Exclusion: N\u002FA","ALL","EXPANDED_ACCESS","Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.",[19,20,21],"Lipodystrophy","Generalized Lipodystrophy (GLD)","Monogenic Obesity (MOB)",[23,24,25],"Leptin (LEP)","Leptin Receptors (LEPR)","Biallelic Loss of Function Variants of the LEP Gene","AVAILABLE","2026-03-10",{"date":29,"type":30},"2026-03-12","ACTUAL",{"name":32,"class":33},"Regeneron Pharmaceuticals","INDUSTRY"]